Soligenix is developing products to treat rare diseases, addressing the lack of FDA-approved treatments for millions of Americans.
2 reports, 1 independent
Updated Aug 7
Gone quiet
- Reports
- 2
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Soligenix is developing products to treat rare diseases, addressing the lack of FDA-approved treatments for millions of Americans.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Ellen Kim is the Principal Investigator for Soligenix trials.Sub-event
- The FDA provides a development grant to Soligenix to support its work on rare disease treatments.Sub-event
- Pfizer and Soligenix committed to making an impact in the pharmaceutical space by improving access to treatments.Sub-event
Soligenix is developing treatments for rare diseases, highlighting the need for more FDA-approved options for Americans.1 source
Keep exploring
The entities involved
- FDA
-
Soligenix (United States)
company in Princeton, United States
Nothing else this week.
Related events
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
Coverage
Newest first; wire copies grouped- GlobeNewswireSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) to
- GlobeNewswireSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) toda